Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 15;13(9):10439-10448.
eCollection 2021.

miR-145-5p inhibits psoriasis progression by regulating the Wnt/β-catenin pathway

Yihan Wang  1 , Yi Cao  2
Affiliations

miR-145-5p inhibits psoriasis progression by regulating the Wnt/β-catenin pathway

Yihan Wang et al. Am J Transl Res. .

Abstract

Objective: This research aimed to probe into the effect of miR-145-5p in psoriasis by regulating Wnt/β-catenin.

Methods: A total of 45 psoriasis patients treated in our hospital were enrolled into an observation group (OG), and other 40 healthy individuals in physical examination over the same period were enrolled into a control group (CG). miR-145-5p in both groups was quantified, and its value in diagnosis and recurrence prediction of psoriasis was analyzed. Additionally, miR-145-5p was transfected into HaCat cells to analyze the biological behaviors of transfected cells, and factors for Wnt/β-catenin pathway inhibition were injected into cells to detect its protein expression in the cells, so as to verify the regulation of miR-145-5p on the Wnt/β-catenin pathway.

Results: with low expression in the serum of psoriasis patients (P<0.05), miR-145-5p was of great application value for diagnosis and recurrence prediction. In the inhibition group, miR-145-5p increased (P<0.05), while Wnt/β-catenin pathway-related proteins decreased (P<0.05). Compared with untreated HaCat cells, the protein expression in HaCat cells treated with XAV-939 decreased (P<0.05). There was no notable difference between the miR-145-5p-mimics+XAV-939 group and the empty vector group in cell proliferation, apoptosis rate, and expression of Wnt3a, Wnt5a, and β-catenin proteins (all P>0.05); but compared with both groups, the miR-145-5p-mimics group showed lower proliferation activity, higher apoptosis rate, and higher expression of Wnt3a, Wnt5a, and β-catenin proteins (all P<0.05).

Conclusion: Up-regulating miR-145-5p can activate the Wnt β-catenin signal pathway, thus inhibiting psoriasis progression.

Keywords: MiR-145-5p; Wnt; psoriasis; β-catenin.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Clinical significance of miR-145-5p for psoriasis. A. Expression of miR-145-5p in peripheral blood of both groups. B. ROC curve of peripheral blood miR-145-5p for diagnosing psoriasis. * indicates P<0.05.
Figure 2
Figure 2
Predictive value of miR-145-5p for recurrence of psoriasis. A. Changes of miR-145-5p expression in patients with recurrence and those without recurrence. B. ROC curve of miR-145-5p for predicting recurrence of psoriasis. * indicates P<0.05.
Figure 3
Figure 3
Effect of miR-145-5p on HaCat cells. A. Expression of miR-145-5p after transfection. B. Proliferation of HaCat cells. C. Apoptosis of HaCat cells. D. Expression of Wnt/β-catenin pathway-related proteins in HaCat cells. * indicates P<0.05. # indicates P<0.05 vs. the miR-145-5p-mimics group; & indicates P<0.05 vs. the miR-145-5p-inhibition group.
Figure 4
Figure 4
Expression of Wnt3a, Wnt5a, and β-catenin proteins in HaCat cells treated with XAV-939. A. Expression of Wnt3a in HaCat cells treated with XAV-939. B. Expression of Wnt5a in HaCat cells treated with XAV-939. C. Expression of β-catenin in HaCat cells treated with XAV-939. * indicates P<0.05.
Figure 5
Figure 5
Effect of miR-145-5p on HaCat cells by Wntβ-catenin signal pathway. A. Cell proliferation. B. Cell apoptosis. C. Expression of Wnt3a, Wnt5a, and β-catenin proteins. * indicates P<0.05; # indicate P<0.05 vs. miR-145-5p-mimics+XAV-939 group; & indicates P<0.05 vs. miR-145-5p-inhibition group.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76:377–390. - PMC - PubMed
    1. Rendon A, Schakel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20:1475. - PMC - PubMed
    1. Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63:278–285. - PMC - PubMed
    1. Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80:27–40. - PubMed
    1. Conrad C, Gilliet M. Psoriasis: from pathogenesis to targeted therapies. Clin Rev Allergy Immunol. 2018;54:102–113. - PubMed

LinkOut - more resources